Home › Kidney Cancer (Renal Cell Carcinoma)
Kidney Cancer (Renal Cell Carcinoma) clinical trials recruiting in the U.S.
134 studies for Kidney Cancer (Renal Cell Carcinoma) are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX35 studies
- New York City, NY27 studies
- Dallas, TX23 studies
- Nashville, TN23 studies
- St. Louis, MO23 studies
- Los Angeles, CA20 studies
- Boston, MA16 studies
- Baldwin Park, CA16 studies
- Philadelphia, PA15 studies
- Pittsburgh, PA15 studies
- Queens, NY15 studies
- Cleveland, OH14 studies
- Jacksonville, FL14 studies
- Rochester, MN14 studies
- San Diego, CA14 studies
- Washington, DC13 studies
- New Haven, CT13 studies
- Columbus, OH13 studies
- Edison, NJ12 studies
- Durham, NC12 studies
- Omaha, NE12 studies
- San Antonio, TX12 studies
- Ann Arbor, MI12 studies
- Phoenix, AZ11 studies
- Portland, OR11 studies
- San Francisco, CA11 studies
- Baltimore, MD10 studies
- Detroit, MI10 studies
- Grand Rapids, MI10 studies
- Atlanta, GA10 studies
- Arlington, VA9 studies
- Seattle, WA9 studies
- Aurora, CO9 studies
- Santa Monica, CA8 studies
- Charlotte, NC8 studies
- Chicago, IL8 studies
- Miami, FL8 studies
- Milwaukee, WI8 studies
- Oklahoma City, OK8 studies
- Denver, CO8 studies
By state
- Alabama7 studies
- Arizona22 studies
- Arkansas6 studies
- California51 studies
- Colorado15 studies
- Connecticut13 studies
- District of Columbia7 studies
- Florida31 studies
- Georgia12 studies
- Idaho4 studies
- Illinois14 studies
- Indiana8 studies
- Iowa9 studies
- Kansas5 studies
- Kentucky9 studies
- Louisiana7 studies
- Maine3 studies
- Maryland17 studies
- Massachusetts18 studies
- Michigan29 studies
- Minnesota20 studies
- Mississippi4 studies
- Missouri23 studies
- Montana3 studies
- Nebraska12 studies
- Nevada4 studies
- New Hampshire4 studies
- New Jersey16 studies
- New Mexico5 studies
- New York36 studies
- North Carolina19 studies
- North Dakota3 studies
- Ohio26 studies
- Oklahoma8 studies
- Oregon11 studies
- Pennsylvania26 studies
- Rhode Island6 studies
- South Carolina12 studies
- South Dakota4 studies
- Tennessee27 studies
- Texas56 studies
- Utah7 studies
- Vermont3 studies
- Virginia13 studies
- Washington12 studies
- West Virginia4 studies
- Wisconsin12 studies
Recently updated studies
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05536141Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07300241Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06265285A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT05155033A Phase 1 Study of the Safety and Tolerability of CTX-10726
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07419841Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT07049926A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06234605Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05287945The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07285044Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 29, 2026 · NCT04981509REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07594106DESTINY-PANTUMOUR04
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07489495Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
Ages 18 to 100 · All sexes · Updated Sep 25, 2026 · NCT07748988Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07293351Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06863311A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07688187Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05267626Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 18, 2026 · NCT07828704From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.